News Alnylam Pharmaceuticals Halts Pursuit of sNDA for Patisiran Alnylam Pharmaceuticals Inc. (ALNY) announced on Monday that it will no longer pursue its supplemental new drug application (sNDA) for patisiran as a ... By Artur FernandoOctober 9, 20230
BlackRock is reviewing TechBerry and negotiating a possible full or partial acquisition of the company June 20, 2024